Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.65 |
| ▸ | DRD4 | P21917 | 2/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725628 | 0.93 | SIGMAR1 (0.56) | SIGMAR1DRD4MCHR1HRH3CCR3 | |
| SCHEMBL27226915 | 0.88 | SIGMAR1 (0.59) | SIGMAR1MEN1KMT2AKCNA3 | |
| SCHEMBL15021069 | 0.88 | SIGMAR1 (0.59) | SIGMAR1MEN1KMT2AKCNA3 | |
| SCHEMBL29260128 | 0.88 | KCNA3 (0.53) | SIGMAR1MEN1KMT2AKCNA3 | |
| SCHEMBL12011091 | 0.87 | KDM4E (0.57) | SIGMAR1DRD4MCHR1MEN1KMT2A | |
| SCHEMBL3351581 | 0.87 | SIGMAR1 (0.60) | SIGMAR1MCHR1HRH3CCR3KCNA3 | |
| SCHEMBL30135707 | 0.87 | KCNA3 (0.52) | SIGMAR1MEN1KMT2AKCNA3 | |
| SCHEMBL15021685 | 0.87 | SIGMAR1 (0.60) | SIGMAR1MEN1KMT2AKCNA3 | |
| SCHEMBL915402 | 0.86 | KMT2A (0.65) | SIGMAR1DRD4MCHR1MEN1KMT2A | |
| SCHEMBL13088854 | 0.86 | KDM4E (0.53) | SIGMAR1MCHR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660303-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | KANCERA AB (SE) | 2023-05-30 | — | — | US | disclosed |
| CN-109563092-A | It can be used as the 2- phenylimidazole of the active inhibitor of mammal tyrosine kinase ROR1 simultaneously [4,5-B] pyridine -7- amine derivative | 坎塞拉有限公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-1229025-A1 | NOVEL QUINAZOLINE DERIVATIVES | Japan Energy Corporation (JP) | 2002-08-07 | — | — | EP | disclosed |
| EP-0111397-B1 | ISOINDOLE DERIVATIVES, PREPARATION, AND USES | Bristol-Myers Company (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4600758-A | 5-SULFAMOYL-3-OXOISOINDOLES WITH ARLYPIPERIDINYL MOIETIES, DIURETICS, HYPOTENSIVES | MEAD JOHNSON & COMPANY (US) | 1986-07-15 | — | — | US | disclosed |
| US-4495194-A | HYPOTENSIVE AGENTS; DIURETICS | MEAD JOHNSON & COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0111397-A1 | Isoindole derivatives, preparation, and uses | Bristol-Myers Company (US) | 1984-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660303-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | ROR1, RORB, RORA | SIGMAR1 2236/4885DRD4 4664/4885MCHR1 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.